Evidence map›Paper›PMID 35848566›Full record

ArticleClinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis

Development and Implementation of an Online Global Pharmacovigilance Certificate Program During the COVID-19 Pandemic.

Thao Doan, Fabio Lievano, Linda Scarazzini, Kate Liebelt, Mark Jaradeh, Bulent Kantarcioglu, Jawed Fareed, W Keith Jones

Open access · goldAbstract read
In one paragraph

Article in Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 49% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Thao DoanPharmacovigilance and Patient Safety, North Chicago, IL, USA.
Fabio LievanoPharmacovigilance and Patient Safety, North Chicago, IL, USA.
Linda ScarazziniPharmacovigilance and Patient Safety, North Chicago, IL, USA.
Kate LiebeltPharmacovigilance and Patient Safety, North Chicago, IL, USA.
Mark JaradehDepartment of Molecular Pharmacology and Neuroscience, 25815Loyola University Chicago, Maywood, IL, USA.ORCID https://orcid.org/0000-0001-8916-7533
Bulent KantarciogluDepartment of Molecular Pharmacology and Neuroscience, 25815Loyola University Chicago, Maywood, IL, USA.
Jawed FareedDepartment of Molecular Pharmacology and Neuroscience, 25815Loyola University Chicago, Maywood, IL, USA.ORCID https://orcid.org/0000-0003-3465-2499
W Keith JonesDepartment of Molecular Pharmacology and Neuroscience, 25815Loyola University Chicago, Maywood, IL, USA.
Loyola University Chicago · USNational Patient Safety Foundation · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pharmacovigilance plays a lifesaving role in the practice of medicine. In 2021, during the Coronavirus Infectious Disease 2019 (COVID-19) pandemic, Loyola University Chicago launched a graduate-level Pharmacovigilance Certificate Program (PV-CERT) and a pre-professional non-graduate Pharmacovigilance Certificate Course (EPEC-PV), to provide students a comprehensive and contemporary understanding of the principles and practices of pharmacovigilance. Formal training in pharmacovigilance through this course provided a structured understanding of how safety data are generated through clinical trials and from real-world evidence as well as the regulatory environment in which data are monitored and interpreted. Pharmacovigilance training is of critical importance, especially during the COVID-19 pandemic, during which several drugs were re-purposed for the management of various stages of COVID-19 without conventional safety data. Moreover, the safety of currently-used vaccines is of concern in some populations. Although anticoagulants and antithrombotic medications are crucial in the management of COVID-19, a clear pharmacovigilance program on their use in this indication is not established. As the century progresses, new diseases and infectious agents will require novel therapies for which the evaluation of benefits versus risks will be as essential as it has been for the current COVID-19 pandemic. As such, the Loyola course and accompanying programs on pharmacovigilance will play a key role in educating the next generation of professionals in pursuing careers in the development of therapies that ultimately improve patient outcomes while maintaining rigorous safety standards.

Indexed as

Communicable DiseasesCOVID-19HumansPandemicsPharmacovigilanceCOVID-19pandemicpharmacovigilancesafety sciences

Identifiers

PMID35848566
PMCPMC9297450
OpenAlexW4285796572

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.